A Cost Per Responder Analysis of Secukinumab Vs Adalimumab Based on A Matching-Adjusted Indirect Comparison For The Treatment of Ankylosing Spondylitis From A German Payer Perspective
Abstract
Authors
P Gunda A Kandhare E Nikoglou SM Jugl J Kneidl K Neidhardt